LAWRENCE, Mass., April 16, 2018 (GLOBE NEWSWIRE) -- Boston Therapeutics Inc. (the “Company” or “BTI”) (OTCQB:BTHE), an innovator in the design, development and commercialization of novel therapeutics for the potential treatment of diabetes and related complications, will hold a conference call on Wednesday, April 18, 2018 at 5:00 p.m. Eastern time (2:00 p.m. Pacific time) to discuss recent business developments, including its recent acquisition of CureDM and recently announced intention to acquire Medical Technology Associates II, Inc. Boston Therapeutics management will host the presentation, followed by a question and answer period.
Date: Wednesday, April 18, 2018
Time: 5:00 p.m. Eastern time (2:00 p.m. Pacific time)
U.S. dial-in: 1-800-263-0877
TOLL/INTERNATIONAL dial-in: 1-323-794-2094
Please call the conference telephone number 5-10 minutes prior to the start time. An operator will register your name and organization. If you have any difficulty connecting with the conference call, please contact ViaVid at toll-free (888) 562-0262 | tel (604) 929-1352.
The conference call will be broadcast live and available for replay at the Investor Relations section of Boston Therapeutics website. A replay of the conference call will be available after 8:00 p.m. Eastern time on the same day through May 02, 2018.
Toll-free replay number: 1-844-512-2921
International replay number: 1-412-317-6671
Replay ID: 2971422
Investor Relations Contact: Loraine V. Upham
About Boston Therapeutics, Inc. www.bostonti.com
Boston Therapeutics, headquartered in Lawrence, MA (OTCQB:BTHE) and with an office in Albuquerque, NM is an innovator in design, development and commercialization of novel compounds to treat diabetes and diabetes related complications. The company has proprietary compounds based on glucose chemistry, peptide chemistry and protein conjugates.
Contact: Boston Therapeutics, Inc.
Loraine Upham, COO
Phone: 603-935-9799
Email: loraine.upham@bostonti.com
www.bostonti.com